Fortress Biotech(FBIOP)

BAY HARBOR ISLANDS, FLBiotechnology1 H-1B visas (FY2023)

Focus: Fortress Biotech is a public biotechnology company developing small molecule therapeutics and novel helminth worm egg-based therapies, operating as a lean R&D-focused organization.

Biopharmaceuticals

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Fortress Biotech

AI assessmentNot Hiring

No open roles listed right now. Follow Fortress Biotech to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$58M

FY2025

Recent News · Fortress Biotech(6)

FinancialSEC 8-K

Apr 21, 2026

8-K Filing: Journey Medical Corp (DERM) (CIK 0001867066) — EXHIBIT 99.1

EXHIBIT 99.1

Help build intelligence for Fortress Biotech

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to highly unconventional therapeutic modality (helminth therapy) offers rare scientific frontier opportunity
Public company status provides liquidity and institutional credibility versus pre-revenue biotech
Lean operation (98% R&D intensity) means high-impact individual contribution potential

Watch Out For

Severe cash burn trajectory: $60.6M net loss in FY2024 on $85M revenue with declining cash runway
Only 1 active job opening suggests minimal hiring and limited career mobility within organization
No clinical programs in trials (Phase 1-3 pipeline: 0) indicates early-stage science with distant commercialization

Generated by Claude from Fortress Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

FinancialNews

Mar 31, 2026

Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties - Stock Titan

Fortress Biotech (NASDAQ: FBIO) turns 2025 profit with $205M PRV sale and new royalties  Stock Titan

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

H-1B (2023): 1 approval

Publications: 5 in PubMed

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$58M32%

R&D Spend

$57M(98%)44%

Net Income

-$46M

Cash

$57M

Source: SEC 10-K Filing

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(5)

Recent peer-reviewed publications with author affiliations at this company

Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIV-associated dementia.

AIDS (London, England)

2024

PMID:37905996

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

2018

PMID:29597002